📊 STXS Key Takeaways
Is Stereotaxis, Inc. (STXS) a Good Investment?
While Stereotaxis demonstrates exceptional 6375% revenue growth and healthy 60.3% gross margins indicating strong unit economics, the company is operationally unviable with -$6.0M operating losses on $6.3M revenue and negative operating cash flow of -$3.4M. At current burn rates, existing cash provides only ~4 years of runway with no clear near-term path to profitability, presenting significant execution risk despite minimal leverage.
Stereotaxis, Inc. Key Strengths (STXS)
- Explosive revenue growth trajectory (6375% YoY) from minimal historical baseline suggests successful product launch or major commercial breakthrough
- Strong gross margins at 60.3% demonstrating attractive unit economics and pricing power for electromedical devices
- Fortress balance sheet with minimal debt (0.02x D/E ratio, only $243.6K long-term debt) and adequate liquidity (1.56x current ratio)
STXS Stock Risks: Stereotaxis, Inc. Investment Risks
- Severe operating loss of -$6.0M on $6.3M revenue indicates operating expense structure is fundamentally misaligned with current scale
- Negative operating cash flow of -$3.4M is unsustainable; existing $14.6M cash provides only ~4 years runway without profitability inflection
- Revenue growth from near-zero base raises sustainability concerns; scale required to reach breakeven unclear and likely requires significant capital or major revenue acceleration
Key Metrics to Watch
- Operating cash flow trajectory and path to cash-flow breakeven
- Revenue growth sustainability and magnitude of next quarters versus 6375% base effect
- Operating expense leverage: whether opex grows slower than revenue as scale increases
Stereotaxis, Inc. (STXS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Stereotaxis, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
STXS Profit Margin, ROE & Profitability Analysis
STXS vs Healthcare Sector: How Stereotaxis, Inc. Compares
How Stereotaxis, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Stereotaxis, Inc. Stock Overvalued? STXS Valuation Analysis 2026
Based on fundamental analysis, Stereotaxis, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Stereotaxis, Inc. Balance Sheet: STXS Debt, Cash & Liquidity
STXS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Stereotaxis, Inc.'s revenue has remained relatively flat over the 5-year period, with a 8% decline. The most recent EPS of $-0.30 indicates the company is currently unprofitable.
STXS Revenue Growth, EPS Growth & YoY Performance
STXS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.3M | -$5.8M | $-0.06 |
| Q3 2025 | $7.5M | -$6.2M | $-0.07 |
| Q2 2025 | $4.5M | -$3.8M | $-0.05 |
| Q1 2025 | $6.9M | -$4.5M | $-0.06 |
| Q3 2024 | $7.8M | -$5.4M | $-0.07 |
| Q2 2024 | $4.5M | -$5.0M | $-0.07 |
| Q1 2024 | $6.5M | -$4.5M | $-0.06 |
| Q3 2023 | $7.7M | -$4.9M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Stereotaxis, Inc. Dividends, Buybacks & Capital Allocation
STXS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Stereotaxis, Inc. (CIK: 0001289340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STXS
What is the AI rating for STXS?
Stereotaxis, Inc. (STXS) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STXS's key strengths?
Claude: Explosive revenue growth trajectory (6375% YoY) from minimal historical baseline suggests successful product launch or major commercial breakthrough. Strong gross margins at 60.3% demonstrating attractive unit economics and pricing power for electromedical devices.
What are the risks of investing in STXS?
Claude: Severe operating loss of -$6.0M on $6.3M revenue indicates operating expense structure is fundamentally misaligned with current scale. Negative operating cash flow of -$3.4M is unsustainable; existing $14.6M cash provides only ~4 years runway without profitability inflection.
What is STXS's revenue and growth?
Stereotaxis, Inc. reported revenue of $6.3M.
Does STXS pay dividends?
Stereotaxis, Inc. does not currently pay dividends.
Where can I find STXS SEC filings?
Official SEC filings for Stereotaxis, Inc. (CIK: 0001289340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STXS's EPS?
Stereotaxis, Inc. has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is STXS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Stereotaxis, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is STXS stock overvalued or undervalued?
Valuation metrics for STXS: ROE of -40.8% (sector avg: 15%), net margin of -93.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is STXS's AI grade for 2026?
Our dual AI analysis gives Stereotaxis, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STXS's free cash flow?
Stereotaxis, Inc.'s operating cash flow is $-3.4M, with capital expenditures of $79.0K. FCF margin is -56.0%.
How does STXS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -93.2% (avg: 12%), ROE -40.8% (avg: 15%), current ratio 1.56 (avg: 2).